Anaptysbio (ANAB) Non Operating Income (2016 - 2026)
Anaptysbio's (ANAB) quarterly Non Operating Income came in at -$18.2 million in Q1 2026, down 55.01% YoY from -$40.5 million in Q1 2025, and down 5.82% on a QoQ basis from -$17.2 million in Q4 2025.
Anaptysbio (ANAB) Non Operating Income (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Non Operating Income data on file, last reported at -$18.2 million in Q1 2026.
- Quarterly Non Operating Income fell 55.01% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$67.4 million (down 67.35% YoY) and the FY2025 annual result came in at -$61.0 million, down 101.34% from the prior year.
- Non Operating Income slipped to -$18.2 million in Q1 2026, from -$17.2 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $424000.0 in Q3 2023 to a low of -$19.6 million in Q3 2025.
- A 5-year average of -$7.2 million and a median of -$4.8 million in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 110.96% — and 2024, when it plunged 15050.0%.
- Tracing ANAB's Non Operating Income over 5 years: stood at -$416000.0 in 2022, then surged by 80.77% to -$80000.0 in 2023, then sank by 15050.0% to -$12.1 million in 2024, then slumped by 41.96% to -$17.2 million in 2025, then slipped by 5.82% to -$18.2 million in 2026.
- The last three Non Operating Income figures came in at -$18.2 million (Q1 2026), -$17.2 million (Q4 2025), and -$19.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -18.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.21 Mn |
| Dec 31, 2025 | -17.21 Mn |
| Sep 30, 2025 | -19.59 Mn |
| Jun 30, 2025 | -12.42 Mn |
| Mar 31, 2025 | -11.75 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Sep 30, 2024 | -10.09 Mn |
| Jun 30, 2024 | -6.33 Mn |
| Mar 31, 2024 | -1.74 Mn |
| Dec 31, 2023 | -80,000.00 |
| Sep 30, 2023 | 424,000.00 |
| Jun 30, 2023 | 298,000.00 |
| Mar 31, 2023 | 146,000.00 |
| Dec 31, 2022 | -416,000.00 |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | -4.76 Mn |
| Mar 31, 2022 | -4.51 Mn |
| Dec 31, 2021 | -1.38 Mn |
| Sep 30, 2021 | 97,000.00 |
| Jun 30, 2021 | 104,000.00 |